Gadolinium-enhanced cardiovascular magnetic resonance: Administered dose in relationship to united states food and drug administration (FDA) guidelines

Journal of Cardiovascular Magnetic Resonance

Volumn 14, Issue 1, 2012, Pages

  Nacif, Marcelo S ^a,b,c   Arai, Andrew E ^d   Lima, Joao A C ^b   Bluemke, David A ^a,e  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

Contrast media; Gadolinium; Heart; Magnetic resonance imaging

Indexed keywords

ECHOVIST; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOLINIUM;

ADULT; AGED; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL TRIAL (TOPIC); CONTRAST ENHANCEMENT; FOOD AND DRUG ADMINISTRATION; HUMAN; LIBRARY; MEDLINE; META ANALYSIS; MULTICENTER STUDY (TOPIC); NEPHROGENIC SYSTEMIC FIBROSIS; PEER REVIEW; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; UNITED STATES; ADOLESCENT; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CHILD; DOSE RESPONSE; DRUG LABELING; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; RISK ASSESSMENT; RISK FACTOR; STANDARD;

ADOLESCENT; ADULT; AGED; CARDIOVASCULAR DISEASES; CHILD; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG LABELING; GADOLINIUM; GUIDELINE ADHERENCE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 84860561477     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1186/1532-429X-14-18     Document Type: Review

References (33)

1. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG, Ho VB, Jerosch-Herold M, Kramer CM, Manning WJ, Patel M, Pohost GM, Stillman AE, White RD, Woodard PK, Circulation 2010 121 2462 2508 20479157
2. Assessment of acute myocardial infarction: current status and recommendations from the North American society for Cardiovascular Imaging and the European Society of Cardiac Radiology. Stillman AE, Oudkerk M, Bluemke D, Bremerich J, Esteves FP, Garcia EV, Gutberlet M, Hundley WG, Jerosch-Herold M, Kuijpers D, Kwong RK, Nagel E, Lerakis S, Oshinski J, Paul JF, Underwood R, Wintersperger BJ, Rees MR, Int J Cardiovasc Imaging 2011 27 7 24 10.1007/s10554-010-9714-0 20972835
3. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM, N Engl J Med 2000 343 1445 1453 10.1056/NEJM200011163432003 11078769
4. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, Sheppard MN, Poole-Wilson PA, Pennell DJ, J Am Coll Cardiol 2006 48 1977 1985 10.1016/j.jacc.2006.07.049 17112987 (Pubitemid 44738448)
5. MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial. Schwitter J, Wacker CM, van Rossum AC, Lombardi M, Al-Saadi N, Ahlstrom H, Dill T, Larsson HB, Flamm SD, Marquardt M, Johansson L, Eur Heart J 2008 29 480 489 10.1093/eurheartj/ ehm617 18208849 (Pubitemid 351264187)
6. Assessment of myocardial perfusion in coronary artery disease by magnetic resonance: a comparison with positron emission tomography and coronary angiography. Schwitter J, Nanz D, Kneifel S, Bertschinger K, Buchi M, Knusel PR, Marincek B, Luscher TF, von Schulthess GK, Circulation 2001 103 2230 2235 11342469 (Pubitemid 32433710)
7. Diagnostic performance of combined cardiac MRI for detection of coronary artery disease. de Mello RA, Nacif MS, Dos Santos AA, Cury RC, Rochitte CE, Marchiori E, Eur J Radiol 2011
8. Early assessment of myocardial salvage by contrast-enhanced magnetic resonance imaging. Hillenbrand HB, Kim RJ, Parker MA, Fieno DS, Judd RM, Circulation 2000 102 1678 1683 11015347
9. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, Bundy J, Finn JP, Klocke FJ, Judd RM, Circulation 1999 100 1992 2002 10556226 (Pubitemid 29529292)
10. Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement. Kellman P, Arai AE, McVeigh ER, Aletras AH, Magn Reson Med 2002 47 372 383 10.1002/mrm.10051 11810682 (Pubitemid 34116807)
11. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Grobner T, Nephrol Dial Transplant 2006 21 1104 1108 16431890
12. Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Abu-Alfa AK, Adv Chronic Kidney Dis 2011 18 188 198 10.1053/j.ackd.2011.03.001 21531325
13. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, Abujudeh HH, Radiology 2011 260 105 111 10.1148/radiol.11102340 21586680
14. [Nephrogenic systemic fibrosis (NSF) - implications for radiology]. Michaely HJ, Thomsen HS, Reiser MF, Schoenberg SO, Radiologe 2007 47 785 793 10.1007/s00117-007-1537-1 17624507 (Pubitemid 47459034)
15. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment - report of 33 cases. Perez-Rodriguez J, Lai S, Ehst BD, Fine DM, Bluemke DA, Radiology 2009 250 371 377 10.1148/radiol.2502080498 19188312
16. Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. Kim RJ, Albert TS, Wible JH, Elliott MD, Allen JC, Lee JC, Parker M, Napoli A, Judd RM, Circulation 2008 117 629 637 10.1161/CIRCULATIONAHA.107.723262 18212288
17. Myocardial first-pass perfusion magnetic resonance imaging: a multicenter dose-ranging study. Wolff SD, Schwitter J, Coulden R, Friedrich MG, Bluemke DA, Biederman RW, Martin ET, Lansky AJ, Kashanian F, Foo TK, Licato PE, Comeau CR, Circulation 2004 110 732 737 10.1161/01.CIR.0000138106.84335.62 15289374 (Pubitemid 39056274)
18. Detection of coronary artery disease by magnetic resonance myocardial perfusion imaging with various contrast medium doses: first European multi-centre experience. Giang TH, Nanz D, Coulden R, Friedrich M, Graves M, Al-Saadi N, Luscher TF, von Schulthess GK, Schwitter J, Eur Heart J 2004 25 1657 1665 10.1016/j.ehj.2004.06.037 15351166 (Pubitemid 39209287)
19. Late gadolinium-enhancement cardiac magnetic resonance identifies postinfarction myocardial fibrosis and the border zone at the near cellular level in ex vivo rat heart. Schelbert EB, Hsu LY, Anderson SA, Mohanty BD, Karim SM, Kellman P, Aletras AH, Arai AE, Circ Cardiovasc Imaging 2010 3 743 752 10.1161/CIRCIMAGING.108.835793 20847191
20. ECG quantification of myocardial scar in cardiomyopathy patients with or without conduction defects: correlation with cardiac magnetic resonance and arrhythmogenesis. Strauss DG, Selvester RH, Lima JA, Arheden H, Miller JM, Gerstenblith G, Marban E, Weiss RG, Tomaselli GF, Wagner GS, Wu KC, Circ Arrhythm Electrophysiol 2008 1 327 336 10.1161/CIRCEP.108.798660 19808427
21. Cardiac MRI in ischemic heart disease. Ishida M, Kato S, Sakuma H, Circ J 2009 73 1577 1588 10.1253/circj.CJ-09-0524 19667487
22. Cardiac magnetic resonance detection and typical appearance of microvascular obstruction following myocardial infarction. Karatzis EN, Pipilis AG, Malios K, Andreou J, Roussakis A, Tsertos F, Danias PG, Hellenic J Cardiol 2009 50 151 154 19329419
23. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. Ho CY, Lopez B, Coelho-Filho OR, Lakdawala NK, Cirino AL, Jarolim P, Kwong R, Gonzalez A, Colan SD, Seidman JG, Diez J, Seidman CE, N Engl J Med 2010 363 552 563 10.1056/NEJMoa1002659 20818890
24. Cardiac magnetic resonance imaging for differentiating new-onset right-sided heart failure. Roentgen P, Fischer D, Schieffer B, Klein G, Circulation 2011 123 1451 1453 10.1161/CIRCULATIONAHA.110.958892 21464060
25. Cardiac involvement in patients with muscular dystrophies: magnetic resonance imaging phenotype and genotypic considerations. Verhaert D, Richards K, Rafael-Fortney JA, Raman SV, Circ Cardiovasc Imaging 2011 4 67 76 10.1161/CIRCIMAGING.110.960740 21245364
26. Incremental prognostic significance of combined cardiac magnetic resonance imaging, adenosine stress perfusion, delayed enhancement, and left ventricular function over preimaging information for the prediction of adverse events. Bingham SE, Hachamovitch R, Circulation 2011 123 1509 1518 10.1161/CIRCULATIONAHA.109.907659 21444886
27. Complementary prognostic values of stress myocardial perfusion and late gadolinium enhancement imaging by cardiac magnetic resonance in patients with known or suspected coronary artery disease. Steel K, Broderick R, Gandla V, Larose E, Resnic F, Jerosch-Herold M, Brown KA, Kwong RY, Circulation 2009 120 1390 1400 10.1161/CIRCULATIONAHA.108.812503 19770399
28. Myocarditis. Cooper LT Jr, N Engl J Med 2009 360 1526 1538 10.1056/NEJMra0800028 19357408
29. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. Abujudeh HH, Rolls H, Kaewlai R, Agarwal S, Gebreananya ZA, Saini S, Schaefer PW, Kay J, J Magn Reson Imaging 2009 30 1335 1340 10.1002/jmri.21976 19937927
30. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, High WA, Kay J, Radiology 2009 253 81 89 10.1148/radiol.2531082160 19709997
31. Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections. Abujudeh HH, Kosaraju VK, Kaewlai R, AJR Am J Roentgenol 2010 194 430 434 10.2214/AJR.09.3099 20093606
32. EuroCMR (European Cardiovascular Magnetic Resonance) registry: results of the German pilot phase. Bruder O, Schneider S, Nothnagel D, Dill T, Hombach V, Schulz-Menger J, Nagel E, Lombardi M, van Rossum AC, Wagner A, Schwitter J, Senges J, Sabin GV, Sechtem U, Mahrholdt H, J Am Coll Cardiol 2009 54 1457 1466 10.1016/j.jacc.2009.07.003 19682818
33. Multi-ethnic study of atherosclerosis: objectives and design. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR Jr, Kronmal R, Liu K, Nelson JC, O'Leary D, Saad MF, Shea S, Szklo M, Tracy RP, Am J Epidemiol 2002 156 871 881 10.1093/aje/kwf113 12397006 (Pubitemid 35215769)